Sushmita Panda's profile photo

Sushmita Panda

Delhi

Pharma Reporter at Citeline

Pharma Reporter at Scrip

Pharma Reporter @PharmaScrip, @Citeline | Alum: @acjindia | tip/lead: [email protected]

Featured in: Favicon financialexpress.com Favicon msn.com Favicon sputniknews.com Favicon indiatvnews.com Favicon spacedaily.com Favicon einnews.com Favicon sundayguardianlive.com Favicon thedailyguardian.com Favicon yerepouni-news.com Favicon informa.com

Articles

  • Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

    1 day ago | insights.citeline.com | Joseph Haas |Sushmita Panda |Alaric DeArment

    Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFoundPlus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

  • Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

    1 week ago | insights.citeline.com | Joseph Haas |Lisa Takagi |Sushmita Panda |Xu Hu

    Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADCAxcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

  • Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

    2 weeks ago | insights.citeline.com | Joseph Haas |Lisa Takagi |Vibha Ravi |Sushmita Panda

    Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To BenzPlus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

  • Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

    3 weeks ago | insights.citeline.com | Sushmita Panda

    Ascletis Plans China Submission After Positive Denifanstat Phase III Acne ResultsValidation Of FASN Inhibition Approach Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China. Promising Phase III results in China trial for Ascletis/Sagimet's novel acne contender. (Shutterstock)

  • Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

    3 weeks ago | insights.citeline.com | Sushmita Panda

    Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 WinNon-Polyp Rhinosinusitis Targeted InitiallyIn a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious. Lyra Eyes US Filing For Drug-Eluting Implant For Non-Polyp Rhinosinusitis (Shutterstock)

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
4K
Tweets
8K
DMs Open
Yes
Sushmita Panda
Sushmita Panda @SushmitaPanda
4 Jun 25

RT @DrLahariya: There is no such thing as an "active case" in COVID-19. #COVID-19 is now a self-limiting illness, with nearly all cases m…

Sushmita Panda
Sushmita Panda @SushmitaPanda
3 Jun 25

RT @TheLancet: 🧵1/ Presented at #ASCO25: New phase 3 trial suggests adding lurbinectedin to first-line treatment extends survival in exten…

Sushmita Panda
Sushmita Panda @SushmitaPanda
3 Jun 25

RT @jarshadnk: People waking up to em-dashes and Oxford commas say that their usage is clear sign of AI writing. This is not true—the em da…